Indian pharmaceutical stocks are in focus ahead of the Q4 FY26 earnings season, with a mix of corporate actions and global market pressures shaping investor sentiment.

Aurobindo Pharma has drawn attention after announcing an Rs 800 crore share buyback, setting April 17 as the record date. The move signals confidence in its balance sheet and comes as several mid- and large-cap pharma companies focus on capital allocation strategies.

At the same time, sector heavyweights such as Dr. Reddy’s Laboratories and Cipla are witnessing heightened investor interest ahead of earnings, even as underlying challenges persist.

The broader outlook for the sector remains cautious. Analysts expect modest revenue growth but pressure on profitability in the March quarter, largely due to continued weakness in the US generics market. The impact of the loss of exclusivity for key products such as Revlimid is expected to weigh on companies with significant US exposure, including Zydus Lifesciences.

In contrast, Sun Pharmaceutical Industries is seen as relatively better positioned, supported by its specialty portfolio and diversified global presence, which helps cushion volatility in generics.

Among other stocks, Lupin Limited is emerging as a potential outperformer on improving operational metrics, while Torrent Pharmaceuticals continues to pursue acquisition-led growth, highlighting ongoing consolidation in the sector.

However, headwinds remain. Pricing pressure in the US, rising input costs, and currency fluctuations are likely to keep margins under strain across the board. Domestic demand continues to provide some stability, but is not sufficient to fully offset global challenges.

Overall, the Indian pharma sector appears to be entering a transition phase, where earnings visibility remains limited and stock-specific triggers—such as buybacks, product pipelines, and regulatory developments—are likely to drive performance in the near term.